ENDPOINTS NEWS18h
Chi­na's biotech boom is threat­en­ing US drug­mak­er­s' dom­i­nance
Stanford University professor Irv Weissman and a colleague published a paper that represented a new way to target some ...
ENDPOINTS NEWS16h
J&J's Spra­va­to wins ex­pand­ed la­bel for de­pres­sion as sin­gu­lar treat­ment
J&J’s Spravato nasal spray received a label expansion on Tuesday, now approved as a standalone treatment for major depressive ...
ENDPOINTS NEWS16h
Sanofi says no sup­ply in­ter­rup­tions af­ter land­ing FDA warn­ing let­ter for US site
A new FDA warning letter for French pharmaceutical company Sanofi cited a handful of issues at its biologics factory in ...
ENDPOINTS NEWS12h
US with­draw­al from WHO could jeop­ar­dize in­for­ma­tion shar­ing
The Trump administration’s decision to withdraw from the World Health Organization could complicate US access to health ...
ENDPOINTS NEWS18h
As­cen­t­age es­ti­mates $133M in pro­ceeds as it plans Nas­daq dual list­ing
Ascentage Pharma seeks $133M via US listing, markets olverembatinib in China with Takeda holding global rights. CEO Dajun ...
ENDPOINTS NEWS19h
With sup­port from NFL own­er Jef­frey Lurie, Ice­landic biotech clos­es Se­ries A for oral Alzheimer's drug
A father-and-son biotech with ties to Iceland and Philadelphia has put together a €26.5 million Series A to develop oral ...
ENDPOINTS NEWS18h
What to make of Unit­ed­Health Group’s re­bate move
UnitedHealth's OptumRx to pass 100% of drug rebates to clients by 2028, but critics say GPO structure may still hide true ...
ENDPOINTS NEWS12h
Re­newed mifepri­s­tone fight will be ear­ly test of Trump’s abor­tion stance in his sec­ond term
A revived legal challenge to the abortion pill mifepristone will be an early test for President Donald Trump’s administration ...
ENDPOINTS NEWS22h
Sion­na and Odyssey end JPM week with IPO fil­ings
Sionna Therapeutics and Odyssey Therapeutics join Metsera and Maze in filing for IPOs, with Sionna focused on cystic fibrosis ...